Does alogliptin increase major adverse cardiovascular events in patients with type 2 diabetes who had had a recent acute coronary syndrome?
Patients with type 2 diabetes who had had a recent acute coronary syndrome
Alogliptin (DPP-4 inhibitor)
Placebo
Major adverse cardiovascular eventscomposite
Alogliptin does not increase the risk of major adverse cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome.
Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Building similarity graph...
Analyzing shared references across papers
Loading...
William B. White
Christopher P. Cannon
Simon Heller
New England Journal of Medicine
Harvard University
University of Chicago
Brigham and Women's Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
White et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69d97bcf94760e72e6a3cb57 — DOI: https://doi.org/10.1056/nejmoa1305889
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: